检体功效检测市场－全球产业规模、份额、趋势、机会、预测：按产品/服务、类型、最终用户、地区和竞争对手划分，2021-2031年

全球检体功效测试市场预计将从 2025 年的 32.6 亿美元成长到 2031 年的 49.5 亿美元，复合年增长率为 7.21%。

这种专门的筛检流程用于检验生物样本的完整性，检测是否存在检体替换、稀释或伪造用于药物分析的样本的行为。推动该市场发展的主要因素是严格的职场安全监管要求，以及在安全至关重要的行业中降低企业责任的必要性。药物滥用的日益猖獗进一步加剧了这一需求，因此需要强有力的检验通讯协定来确保检测的准确性。例如，美国药物滥用和精神健康服务管理局 (SAMHSA) 在 2024 年报告称，过去一年中报告使用过非法药物的人数比例上升至 25.5%，凸显了采取有效筛检措施的紧迫性。

儘管存在这些成长要素，但由于样本处理技术的日益复杂化，例如使用高品质的合成尿液和先进的掩蔽剂，市场面临着巨大的挑战。这些变通方法迫使实验室持续投资于复杂的分析技术，导致营运成本增加。此外，这也为努力维持全面有效性标准的小规模实验室带来了财务障碍。

市场驱动因素

全球非法药物滥用日益猖獗的是检体有效性检测市场的主要驱动力，也因此更需要严格的筛检程序来验证生物检体的真实性。随着国际毒品消费率的上升，检测实验室不得不处理更多样本，这从统计学角度来看，增加了遇到被篡改或替换以掩盖近期吸毒行为的样本的可能性。这种消费量的激增迫使检测机构将有效性检体纳入其分析流程的标准环节，以防止出现假阴性结果并维持检测的准确性。根据联合国毒品犯罪防制署发布的《2024年世界毒品报告》，2022年全球吸毒人数达到2.92亿，比过去十年增长了20%，凸显了采取强有力的检验措施的必要性。

市场成长也受到职场药物检测和企业安全计画扩展的推动，尤其是在交通运输和製造业等安全至关重要的行业。雇主越来越强制要求进行包括疗效参数在内的全面筛检，以降低法律责任并维护职业安全标准，这促使商业检测实验室采用自动化疗效检测来应对激增的员工检体。根据Quest Diagnostics发布的2024年5月年度药物检测指数，2023年美国员工的整体药物阳性率维持在5.7%的水平，凸显了雇主面临的持续挑战。此外，欧洲药物和药物依赖监测中心估计，2024年欧盟约有2,280万成年人在过去一年中使用过大麻，这强调了製定统一的国际疗效标准的必要性。

市场挑战

检体处理技术的日益复杂化是全球检体有效性检测市场面临的主要阻碍因素。随着越来越多的人使用先进的合成尿液和掩蔽剂来规避标准筛检，实验室被迫投入巨资研发高精度分析技术。这种需求显着增加了营运成本和资金需求，对缺乏资源支持全面有效性标准的小规模实验室而言，构成了巨大的财务障碍。

因此，高成本最终转嫁给了终端用户，随着服务供应日益集中在大型营运商手中，市场的扩充性也下降。根据美国国家无毒工作场所联盟（National Drug-Free 职场 Alliance）预测，到2024年，检体替换的发生率预计将激增600%以上，凸显了此类规避手段的快速蔓延。篡改行为的急剧增加迫使该行业不断投入资源进行昂贵的检验系统升级，这直接阻碍了市场的财务永续性和成长。

市场趋势

为了防止篡改，口腔液检体检验检测作为一种替代传统尿液检查的方法，正被日益广泛地采用。与需要保护隐私的尿液采集不同，口腔液检体的采集是在直接观察下进行的，这显着降低了检体被替换或被合成药物污染的风险。此方法无需二次化学分析即可自然提高检体的可靠性，从而加速了其在法规结构中的应用。根据First Advantage发布的《2024年度趋势报告》，在过去两年中，基于口腔液的药物筛检使用量增加了74%，目前占所有筛检的30%。这表明检测策略正在转向一种能够从根本上确保检体完整性的检测方式。

同时，市场正转向照护现场(POC) 解决方案，以在安全至关重要的领域促进即时决策。各机构越来越多地采用携带式诊断工具，在现场检验检体的有效性，从而有效避免中心检查室处理带来的延误和储存复杂性。这些设备通常整合了自动有效性检查功能，可即时确保检体的充足性和真实性。根据 OraSure Technologies 发布的 2024 年第三季财报，诊断业务营收年增 13%。这主要得益于快速检测产品的强劲销售，凸显了业界对能够提供即时检验结果的分散式筛检方法的日益依赖。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：检体功效测试的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品/服务分类（试剂、校正试剂/品管、检测试剂盒、耗材、服务）
  • 按类型（检查室检测、快速/即时检测）
  • 按最终使用者（职场、药物筛检检查室、疼痛管理中心、戒毒康復中心等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美检体功效测试市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章 欧洲检体功效测试市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区检体功效检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章 中东和非洲检体功效测试市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲检体功效测试市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球检体功效检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• Puritan Medical Products, LLC
• Becton and Dickinson Company
• Lucence Health Inc.
• Hardy Diagnostics Inc
• Medline Industries, LP
• Titan Biotech Ltd.
• Miraclean Technology Co., Ltd
• Starplex Scientific Inc.
• Diasorin SpA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Specimen Validity Testing Market is projected to expand from USD 3.26 Billion in 2025 to USD 4.95 Billion by 2031, reflecting a CAGR of 7.21%. This specialized screening process is utilized to verify the integrity of biological samples by detecting attempts to substitute, dilute, or adulterate specimens submitted for drug analysis. The market is primarily driven by strict regulatory mandates concerning workplace safety and the need for organizations to minimize liability in safety-sensitive industries. This demand is further amplified by the rising prevalence of substance misuse, which necessitates robust verification protocols to ensure test accuracy; for instance, the Substance Abuse and Mental Health Services Administration reported in 2024 that the proportion of individuals reporting illicit drug use in the past year rose to 25.5 percent, highlighting the urgent need for effective screening measures.

Despite these positive growth factors, the market faces significant challenges due to the evolving sophistication of sample tampering methods, such as the use of high-quality synthetic urine and advanced masking agents. These evasion tactics compel laboratories to continuously invest in complex analytical technologies, which increases operational costs and creates financial barriers for smaller testing facilities attempting to maintain comprehensive validity standards.

Market Driver

The rising global prevalence of illicit substance abuse acts as a primary catalyst for the specimen validity testing market, creating a critical need for rigorous screening protocols to confirm the authenticity of biological samples. As drug consumption rates increase internationally, laboratories must handle higher volumes of test subjects, which statistically raises the probability of encountering adulterated or substituted specimens designed to mask recent use. This surge in consumption forces testing facilities to integrate validity checks as a standard part of the analytical workflow to prevent false negatives and maintain accuracy. According to the United Nations Office on Drugs and Crime's 'World Drug Report 2024', the number of people using drugs globally reached 292 million in 2022, a 20 percent increase over the previous decade, underscoring the necessity for robust verification measures.

Market growth is further propelled by the expansion of workplace drug testing and corporate safety programs, particularly within safety-sensitive sectors like transportation and manufacturing. Employers are increasingly mandating comprehensive screening that includes validity parameters to mitigate legal liability and uphold operational safety standards, leading commercial laboratories to adopt automated validity testing to manage the influx of workforce samples. According to Quest Diagnostics' 'Annual Drug Testing Index' from May 2024, the general United States workforce drug positivity rate remained at 5.7 percent in 2023, highlighting the ongoing challenge employers face. Additionally, the European Monitoring Centre for Drugs and Drug Addiction estimated in 2024 that approximately 22.8 million adults in the EU used cannabis in the last year, reinforcing the need for consistent international validity standards.

Market Challenge

The evolving sophistication of sample tampering methods represents a substantial restraint on the Global Specimen Validity Testing Market. As individuals increasingly utilize advanced synthetic urine and masking agents to bypass standard screens, laboratories are compelled to invest in costly, high-precision analytical technologies. This necessity drastically raises operational expenses and capital requirements, creating significant financial barriers for smaller testing facilities that lack the resources to support such comprehensive validity standards.

Consequently, the market experiences reduced scalability as higher costs are passed to end-users and service availability becomes concentrated among larger providers. According to the National Drug-Free Workplace Alliance, the incidence of substituted urine specimens surged by over 600 percent in 2024, highlighting the rapid escalation of these evasion tactics. This sharp rise in tampering forces the industry to continuously divert resources toward expensive verification upgrades, which directly impedes the financial viability and expansion of the market.

Market Trends

The adoption of oral fluid specimen validity testing is gaining traction as a tamper-resistant alternative to traditional urine screening. Unlike urine collection, which requires privacy, oral fluid samples are collected under direct observation, significantly mitigating the risk of substitution or synthetic adulteration. This method naturally enhances specimen validity without requiring extensive secondary chemical analysis, driving its integration into regulatory frameworks. According to First Advantage's '2024 Annual Trends Report', the utilization of oral fluid-based drug screens grew by 74 percent over the last two years, now comprising 30 percent of all screening, indicating a strategic pivot toward testing matrices that inherently secure sample integrity.

Simultaneously, the market is shifting towards point-of-care (POC) testing solutions to facilitate immediate decision-making in safety-sensitive sectors. Organizations are increasingly deploying portable diagnostic tools that verify sample validity on-site, effectively bypassing the delays and custody complexities associated with central laboratory processing. These devices frequently incorporate automated validity checks to ensure specimen sufficiency and authenticity in real-time. According to OraSure Technologies' 'Third Quarter 2024 Financial Results', diagnostics segment revenues increased 13 percent year-over-year, driven by robust sales of rapid testing products, highlighting the industry's expanding reliance on decentralized screening methods that deliver instant, verified results.

Key Market Players

• Thermo Fisher Scientific Inc.
• Puritan Medical Products, LLC
• Becton and Dickinson Company
• Lucence Health Inc.
• Hardy Diagnostics Inc
• Medline Industries, LP
• Titan Biotech Ltd.
• Miraclean Technology Co., Ltd
• Starplex Scientific Inc.
• Diasorin S.p.A.

Report Scope

In this report, the Global Specimen Validity Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Specimen Validity Testing Market, By Product and Service

• Reagents
• Calibrators and Controls
• Assay Kits
• Disposables
• Services

Specimen Validity Testing Market, By Type

• Laboratory Testing
• Rapid/PoC Testing

Specimen Validity Testing Market, By End User

• Workplaces
• Drug Screening Laboratories
• Pain Management Centers
• Drug Rehabilitation Centers
• Others

Specimen Validity Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Specimen Validity Testing Market.

Available Customizations:

Global Specimen Validity Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Specimen Validity Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product and Service (Reagents, Calibrators and Controls, Assay Kits, Disposables, Services)
  • 5.2.2. By Type (Laboratory Testing, Rapid/PoC Testing)
  • 5.2.3. By End User (Workplaces, Drug Screening Laboratories, Pain Management Centers, Drug Rehabilitation Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Specimen Validity Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product and Service
  • 6.2.2. By Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Specimen Validity Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product and Service
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Specimen Validity Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product and Service
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Specimen Validity Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product and Service
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End User

7. Europe Specimen Validity Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product and Service
  • 7.2.2. By Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Specimen Validity Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product and Service
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Specimen Validity Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product and Service
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Specimen Validity Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product and Service
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Specimen Validity Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product and Service
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Specimen Validity Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product and Service
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Specimen Validity Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product and Service
  • 8.2.2. By Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Specimen Validity Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product and Service
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Specimen Validity Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product and Service
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Specimen Validity Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product and Service
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Specimen Validity Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product and Service
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Specimen Validity Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product and Service
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Specimen Validity Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product and Service
  • 9.2.2. By Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Specimen Validity Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product and Service
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Specimen Validity Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product and Service
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Specimen Validity Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product and Service
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End User

10. South America Specimen Validity Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product and Service
  • 10.2.2. By Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Specimen Validity Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product and Service
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Specimen Validity Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product and Service
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Specimen Validity Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product and Service
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Specimen Validity Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Puritan Medical Products, LLC
• 15.3. Becton and Dickinson Company
• 15.4. Lucence Health Inc.
• 15.5. Hardy Diagnostics Inc
• 15.6. Medline Industries, LP
• 15.7. Titan Biotech Ltd.
• 15.8. Miraclean Technology Co., Ltd
• 15.9. Starplex Scientific Inc.
• 15.10. Diasorin S.p.A.

16. Strategic Recommendations

17. About Us & Disclaimer